<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical predictors and potential therapeutic implications of microembolic signals (<z:chebi fb="28" ids="39005,39010">MES</z:chebi>) were investigated in 104 patients with <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> associated with high-risk (n = 60) or low-risk (n = 44) cardiac emboligenic conditions </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with artificial valves and <z:hpo ids='HP_0100546'>carotid stenosis</z:hpo> were excluded </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="28" ids="39005,39010">MES</z:chebi> counts were based on 30-min bilateral middle cerebral artery transcranial Doppler (TCD) monitoring recordings </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="28" ids="39005,39010">MES</z:chebi> were detected in 15 subjects (14%) </plain></SENT>
<SENT sid="4" pm="."><plain>The mean number of <z:chebi fb="28" ids="39005,39010">MES</z:chebi> per hour was 1.9 </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="28" ids="39005,39010">MES</z:chebi> prevalence and counts were influenced neither by age, gender or type of cerebral event, nor by <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">cardiac disease</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="28" ids="39005,39010">MES</z:chebi> were more frequently detected and greater in number in patients with multiple cerebral ischemic events and in subjects monitored within 1 month of the last event </plain></SENT>
<SENT sid="7" pm="."><plain>By multiple logistic regression, TCD recording within 1 month of the last event [Odds ratio (OD) = 13.5; 95% confidence intervals (CI) = 3.3-54.3] and multiple cerebral events (OD = 4.7; 95% CI = 1.3-17.3) were the best <z:chebi fb="28" ids="39005,39010">MES</z:chebi> predictors </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="28" ids="39005,39010">MES</z:chebi> were detected in 40% (4/10) of patients on <z:chebi fb="5" ids="28304">heparin</z:chebi>, 5% (2/4) of untreated subjects and 13% (5/39) of those on antiplatelet drugs </plain></SENT>
<SENT sid="9" pm="."><plain>For patients on <z:chebi fb="8" ids="10033">warfarin</z:chebi>, <z:chebi fb="28" ids="39005,39010">MES</z:chebi> counts and prevalence were similar in subjects with international normalized ratios (INR) below and within/above the therapeutic range </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="28" ids="39005,39010">MES</z:chebi> were detected in only 2 out of 16 subjects with INR &lt;2 and in 1 with INR &gt;2 </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="28" ids="39005,39010">MES</z:chebi> detection can be potentially relevant to the selection of antithrombotic treatment in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> associated with cardioembolic disease, but further studies are necessary to assess its effectiveness as an additional guide to monitor oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> intensity </plain></SENT>
</text></document>